A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals ...

Casgevy was developed in collaboration with narrow-moat Vertex Pharmaceuticals for the treatment of two blood disease: transfusion-dependent beta-thalassemia and sickle-cell anemia. Casgevy received ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

CASGEVY is a collaboration product between CRISPR Therapeutics and Vertex Pharmaceuticals, and as part of an amendment ... an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical ...